Vast Therapeutics
  • Home
  • About
    • Company Overview
    • Our Team
    • Scientific Advisory Board
    • Careers
  • Technology
    • Nitric Oxide
    • Need for Antibiotic Alternatives
    • Broad Spectrum Efficacy
  • Applications
    • Cystic Fibrosis
    • NTM Lung Disease
    • Other Targets
  • Media
  • Investors

Media

Vast Therapeutics Announces Series A Funding

12/5/2018

 

Read More

Vast Therapeutics (formerly Novoclem) Announces Results Showing Eradication of all In Vitro Tested Multi-Drug Resistant Bacteria and a 99% Reduction of Nontuberculous Mycobacteria (NTM) in Animal Model.

5/22/2018

 

Read More
Forward>>


    Archives

    January 2021
    September 2020
    October 2019
    May 2019
    January 2019
    December 2018
    May 2018
    February 2018
    January 2018
    November 2017
    October 2017
    July 2017
    April 2017
    January 2017


    ​Categories

    All
    Anthrax
    BIOC11
    BIOC51
    Biotech Showcase
    CED
    CFF
    Conference
    COVID-19
    Cystic Fibrosis
    Funding
    GAIN Act
    NACFC
    NCBIO
    News Article
    Nitric Oxide
    NTM Animal Model
    Partnership
    Patent
    Pathogens
    Press Release
    QIDP Status
    SARS-CoV-2
    Superbugs
    Therapy
    Video

    RSS Feed

Vast Therapeutics logo - white

Address

​4222 Emperor Blvd. Suite 470
​Durham, NC 27703

Contact Us

info@vasttherapeutics.com

Sector

Biopharmaceutical

Industry

​Biotechnology

    Sign Up for Email Alerts

Submit
​Forward-Looking Statement | Privacy | Terms of Use | Site Map
​Copyright © 2021 Vast Therapeutics - All Rights Reserved
Picture
  • Home
  • About
    • Company Overview
    • Our Team
    • Scientific Advisory Board
    • Careers
  • Technology
    • Nitric Oxide
    • Need for Antibiotic Alternatives
    • Broad Spectrum Efficacy
  • Applications
    • Cystic Fibrosis
    • NTM Lung Disease
    • Other Targets
  • Media
  • Investors